Butterfliesnkisses Leaks - Brightlocal News
Remibrutinib demonstrated statistically significant superiority in both primary endpoint scenarios (cfb in uas7 and iss7/hss7 at week 12) vs placebo in patients with csu remaining symptomatic with … The primary efficacy endpoint in the remix-1 and remix-2 trials was the absolute change from baseline in the weekly urticaria activity score (uas7) at week 12. [2] Review the study design for rhapsido® (remibrutinib) from remix-1 and remix-2, two phase 3 trials.
